News

A group of UK professors and scientists efforts to identify possible direct therapeutic approaches to treat COVID-19 was published in the Perspectives section of the most recent issue of Science, a journal of the American Association for the Advancement of Science (AAAS).

UK researchers have launched antibody testing that will help to understand what immunity to COVID-19 really means. The research is part of UK’s CURE Alliance team, which is uniting UK researchers across disciplines in the fight against the novel coronavirus.

“We are pleased to be able to offer this clinical trial to patients with COVID-19 in Kentucky. While there is no standard treatment for COVID-19, this trial gives us the ability to test multiple therapies rapidly in order to identify the most promising agents.”

“So far, there have been no findings in North America outside of the Pacific Northwest, but we do have some similar looking insects in Kentucky that could cause people to think they have seen one.”

“By putting forth these efforts today, we are ensuring the availability of our collections and data for future use by researchers, educators and the general public."

The Kentucky Conference on Health Communication (KCHC), which was supposed to be held April 2-4, 2020, at the Hyatt Regency in Lexington, made the swift change to a virtual conference amid the COVID-19 pandemic.

It cannot be seen, smelled or tasted, and people are exposed by breathing radon in air when it comes in through gaps and cracks in their homes. It is the second-leading cause of lung cancer after tobacco smoking.

According to the report, confirmed COVID-19 cases in the Commonwealth would have reached a staggering 45,000 by April 25 without any state-imposed measures. For comparison, the current total of confirmed COVID-19 cases is fewer than 4,000.

“Both areas will answer important questions about how platelets work, which could directly contribute to drug development for human diseases, especially thrombotic diseases and chronic viremia,” Whiteheart said.

A new study led by UK researcher April Young and Emory researcher Hannah Cooper shows that a number of pharmacies in the Appalachian region of Kentucky are limiting the dispensing of buprenorphine, a medication used to treat opioid use disorder (OUD).